MedTrace Logo

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

NCT00500331 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2017-12-06

Study results available
· View outcomes & findings →

Summary

This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment naive patients with T2DM

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GSK189075

Experimental Drug

DRUG

pioglitazone

Active Control

OTHER

Placebo

Placebo Comparator

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-23
Primary Completion
2008-02-14
Completion
2008-02-14

Countries

  • United States
  • Argentina
  • Bulgaria
  • Chile
  • Costa Rica
  • Czechia
  • Germany
  • Hungary
  • India
  • Latvia
  • Lithuania
  • Mexico
  • New Zealand
  • Peru
  • Poland
  • Puerto Rico
  • Romania
  • Russia
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500331 on ClinicalTrials.gov